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ABSTRACT
Background: Irinotecan use is limited due to severe toxicity. Preconditioning by 
fasting (PBF) protects against side effects of irinotecan while preserving its antitumor 
activity. The mechanisms underlying the effects of PBF still need to be elucidated. 
Here, we investigated the transcriptional responses of PBF on irinotecan in both tumor 
and healthy liver tissue. 
Experimental approach: Male BALB/c mice were subcutaneously injected with 
C26 colon carcinoma cells. Twelve days after tumor inoculation, two groups were 
fasted for three days and two groups were allowed food ad libitum (AL). Subsequently, 
both groups received one dose of irinotecan. Twelve hours after administration mice 
were sacrificed and blood, tumor and liver tissue were harvested. Blood samples were 
analyzed to determine liver, kidney and bone marrow function, tissues were used for 
transcriptome analyses.
Key results: The AL irinotecan group showed worsened organ function and 
decreased leukocyte numbers. These effects were abated in PBF animals. PBF led to 
an altered transcriptional response in the liver of irinotecan-treated mice, including 
decreased cellular injury and increased stress resistance. Hepatic metabolism of 
irinotecan was also significantly changed due to PBF. The transcriptional response 
of tumor tissue observed after PBF was hardly affected compared to AL fed animals. 
Conclusions: Transcriptional changes after PBF to irinotecan treatment 
showed an improved protective stress response in healthy liver but not in tumor 
tissue, including changes in irinotecan metabolism. These data help to unravel the 
mechanisms underlying the effects of fasting on irinotecan and help to improve 
outcome of chemotherapeutic treatment in cancer patients.
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INTRODUCTION
Colorectal cancer (CRC) is the second most 
diagnosed cancer in women and the third most diagnosed 
in men. Estimated new colorectal cancer cases account 
for 1.4 million cases and 693,900 deaths worldwide 
occurring in 2012 [1]. At initial presentation, 15–20% 
of patients already have liver metastases and another 
45% is diagnosed with liver metastases in the follow-up 
after resection of the primary tumor [2]. Irinotecan is a 
pro-drug of the topoisomerase-I inhibitor SN-38, and is 
applied in first and second line chemotherapy treatment 
for colorectal carcinoma [3, 4]. However, irinotecan can 
induce severe and unpredictable side effects including 
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myelosuppression, diarrhea, and in some cases even death 
as a complication of side effects [5]. 
Dietary restriction (DR) is a method to trigger highly 
conserved survival mechanisms that enhance the resistance 
of organisms against stressors and diseases [6]. We 
recently showed that three days of fasting prior to a toxic 
dose of irinotecan significantly prevented the occurrence 
of side effects in Apc-mutant mice [7]. Furthermore, 
tumor size and proliferation were reduced equally in ad 
libitum (AL) fed and fasted animals. Levels of the active 
metabolite of irinotecan, SN-38, were significantly lower 
in plasma and liver tissue from fasted mice, indicating that 
dietary preconditioning was able to reduce the systemic 
toxicity of SN-38 while the phenotypical effect on tumor 
tissue remained unaltered [7, 8]. These data support the 
concept of differential stress resistance (DSS), which 
states that tumor cells are unable to elicit a protective 
response since they remain driven towards growth due 
to mutations in onco- and tumor suppressor genes [8, 9]. 
However, the molecular mechanisms that govern these 
processes remain largely unknown.
Insight into these mechanisms could facilitate 
translational research into clinical practice since it may 
reveal alternative approaches to DR such as specialized 
forms of DR or DR-mimetics which may induce similar 
effects without the disadvantages of fasting, including 
additional body weight loss in cancer patients. Therefore, 
in this study we investigated the transcriptional responses 
to preconditioning by fasting (PBF) and irinotecan 
exposure in tumor and in healthy liver tissue. 
RESULTS
Fasting induces a chemoprotective phenotype in 
the liver
Male BALB/c mice with subcutaneous C26 colon 
carcinoma tumors were divided over a group fed ad 
libitum (AL) and a group with preconditioning by fasting 
(PBF) for three days, after which both groups received 
irinotecan intraperitoneally. All mice were subsequently 
fasted for two hours followed by AL access to food for 10 
hours, until the moment of sacrifice. The mice in the AL 
irinotecan group consumed on average 2.9 grams of chow 
per mouse in this period. The PBF irinotecan group had 
average intake of 3.5 grams per mouse (data not shown). 
Induction of toxicity by irinotecan and possible 
protective effects of PBF were determined via markers 
of general (LDH) and liver specific (ALT and AST) 
cellular injury, and kidney function (urea and creatinine). 
Serum measurements of these markers are known to 
increase upon cell damage and cell death or kidney 
dysfunction. Leukocyte depletion is a common side 
effect of irinotecan treatment and therefore, leukocyte 
numbers were used as markers of bone marrow toxicity. 
Administration of irinotecan in mice fed AL led to liver 
and kidney injury as seen by high levels of AST, LDH 
(Figure 1A), and urea (Figure 1B). In the PBF irinotecan 
group these markers were on average affected to lesser 
extent than in the AL irinotecan group and both LDH and 
urea levels were significantly lower in the PBF irinotecan 
compared to the AL irinotecan group. Irinotecan caused 
a depletion of leukocytes in AL fed mice, but not in 
PBF animals (Figure 1C). Collectively, these results 
confirm that fasting induces a systemic chemo-protective 
phenotype [10].
Liver transcriptome analysis
To investigate the chemo-protective phenotype 
induced by PBF after irinotecan exposure at the molecular 
level in healthy and tumor tissue, the transcriptomes of 
liver and tumor tissue were directly compared between 
irinotecan exposed AL and PBF mice.
Principal component analysis 
To investigate variability between the irinotecan-
treated groups, we performed an unbiased principal 
component analysis (PCA) including all probe sets in 
the microarray of liver tissue, including 95% confidence 
intervals (CI). When comparing liver tissue of AL 
irinotecan and PBF irinotecan, 48.9% of the variance was 
explained by principal component (PC) 1 and 15.0% by 
PC2 (Figure 2). A pattern of distinct clustering of the two 
groups was seen. The PBF irinotecan group had a smaller 
CI than de AL irinotecan group, and the groups had no 
overlap. These data point towards a differently regulated 
and homogeneous response to irinotecan in the liver due 
to PBF. 
Expression and pathway analyses
To compare expression profiles between 
the different experimental groups, the numbers of 
differentially expressed probe sets (DEPS) were 
calculated. In the liver, 3,636 DEPS were found between 
the AL irinotecan and the PBF irinotecan groups, with 
1,554 DEPS downregulated and 2,082 upregulated. To 
explore canonical pathways enriched by PBF, the 3,636 
DEPS resulting from the comparison AL irinotecan 
versus PBF irinotecan were analyzed. A total of 41 
pathways were found to be regulated, defined by a 
significance of P < 0.05 and a z-score of >1 or <1 (Table 
1). Of these 41 pathways, 32 were activated and nine 
were inhibited. Upregulated pathways were mainly 
involved in in biosynthesis of fatty acids, lipids and 
hormones. Another class overrepresented was amino 
acid degradation, mainly (iso)leucine, valine and 
tryptophan degradation pathways. Two other pathways 
involved in oxidative stress and injury, glutathione-
mediated reactions and NRF-mediated stress response, 
were upregulated as well. Analyses of the downregulated 
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pathways classified these mainly as response to injury 
and cellular proliferation as well as cytokine signaling. 
Xenobiotic metabolism appeared reduced as indicated 
by inhibition of the aryl hydrocarbon receptor (AHR) 
pathway. Analysis of upstream transcription factors 
(TFs) revealed activated TFs involved in stress 
resistance, including NRF1, NRF2 and PPARg, as 
well as upregulation of metabolic TFs, including 
SREBF1 and SREBF2 (Supplementary Table 1). Of the 
downregulated TFs, GATA binding proteins were mainly 
represented as well as proto-oncogenes including MYB 
and ETS1. 
Tumor transcriptome analysis
Principal component analysis
Next, the transcriptomes of the tumor samples were 
analyzed using a similar approach as for the liver samples. 
With a total of 39.8% of the variance explained by PC1 
and 19.4% by PC2, the PCA plot of the tumor tissue of 
the two experimental groups showed high heterogeneity 
among the groups with large intragroup variability 
(Figure 3). The AL and PBF irinotecan groups were not 
clearly separated as clusters as shown by the overlapping 
95% CIs. These PCA plots show a heterogeneous response 
Figure 1: Serum markers 12 hours after irinotecan administration to ad libitum (AL) or preconditioned by fasting 
(PBF) mice. (A) Markers of liver function: aspartate transaminase (AST), alanine transaminase (ALT) and lactate dehydrogenase (LDH). 
(B) Markers of kidney function: urea and creatinine. (C) Leukocyte number. *=P < 0.05, **=P < 0.01. 
Oncotarget2227www.oncotarget.com
of tumor tissue treated with irinotecan, and this response 
was not altered by three days of PBF. 
Expression and pathway analyses 
Calculation of the number of DEPS in the tumor 
tissue was done similarly as in the liver.  One hundred and 
sixty DEPS were found between the AL irinotecan and 
the PBF irinotecan groups with 95 DEPS downregulated 
and 65 upregulated. Pathway analysis was performed 
of the 160 DEPS differentially regulated between AL 
irinotecan and fasting irinotecan in tumor tissue. This 
analysis revealed no enriched pathways, which suggests 
that fasting had no significant effect on the transcriptome 
of tumor tissue. Since no pathways were differentially 
regulated, analysis of upstream transcription was not 
performed.
Irinotecan metabolism related gene expression 
profiles in liver and tumor tissue 
We have previously shown that both irinotecan 
and its active metabolite SN-38 levels are lower in the 
livers and in plasma of PBF mice, compared to AL fed 
mice [10]. Here, we examined specifically expression 
differences of genes coding for proteins involved in 
the metabolism and transportation of irinotecan, using 
the AL irinotecan group as a reference (Figure 4A). In 
the liver, mRNA expression of Ces1, Ces2 and Ces3 
was upregulated by PBF. Of the alternative conversion 
pathway to SN-38, via cytochrome P450  (Cyp)3a11, 
Cyp3a41, Cyp3a13 and Ces3, the expression levels of 
Cyp3a11, Cyp3a41 and Ces3 were upregulated whereas 
Cyp3a13 was downregulated. The ATP binding cassette 
subfamilies (Abc) C and Abcg, involved in the transport 
of SN-38 out of the cell, showed lower expression after 
PBF compared to AL irinotecan-treated liver tissue 
(Figure 4B). Ugt1a1, also involved in the transport of 
SN-38 out of the cell as well as conversion of SN-38 to 
the inactive metabolite SN-38G, was not differentially 
regulated. The expression levels of these genes were 
not or hardly affected by PBF in tumor tissue, with the 
exception of Abcg2 which was downregulated due to PBF 
(Figure 4A). These data suggest a higher conversion rate 
of irinotecan to SN-38 due to PBF, while the transport 
out of the cell appears inhibited. In tumor tissue, the 
same genes were not or only marginally affected due to 
fasting.
DISCUSSION
In this study, we confirm that PBF prior to treatment 
with irinotecan is able to reduce liver toxicity as well as 
bone marrow depression in mice carrying subcutaneous 
colorectal carcinoma. Previously, we showed that these 
signs of somatic resistance to irinotecan were accompanied 
by a reduction in other side effects as body weight loss 
and diarrhea without compromising the antitumor effect 
[7, 10]. Here we set out to retrieve mechanistic insights in 
the chemoprotective effects of BPF through transcriptomic 
analyses of healthy liver and tumor tissue after treatment 
with irinotecan. 
Since the most prominent effect of PBF is the 
reduction of toxic side effects of chemotherapy, its effects 
should be sought primarily in healthy tissue including 
the liver in which the majority of its drug metabolism 
takes place. In this study, PCA showed that irinotecan 
Figure 2: Unbiased principal component analyses (PCA) of liver samples, based on all probe sets in the microarray. 
Principal component (PC) 1 is depicted on the x-axis and PC2 is depicted on the y-axis, including the percentage of variance explained by 
each PC. Each symbol represents one sample of one mouse. Samples of the same group are shown in the same color. Colored field represents 
95% confidence intervals of the group with the circles in the same color. Abbreviations: AL, ad libitum; PBF, preconditioned by fasting. 
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Table 1: Overview of the top overrepresented canonical pathways in liver ranked by their z-score
Liver – AL irinotecan vs. Fasted irinotecan
Canonical pathway Pathway classification P-value Genes ratio Z-score
Superpathway of Cholesterol Biosynthesis Fatty acids and lipids biosynthesis 3.14E-02 19/28 (67.9%) +4.359
tRNA Charging Aminoacyl-tRNA charging; biosynthesis 2.41E-06 16/39 (41.0%) +4.000
Glutathione-mediated Detoxification Detoxification 4.18E-04 11/31 (35.5%) +3.317
Cholesterol Biosynthesis I/II/III Fatty acids and lipids biosynthesis 7.98E-08 10/13 (76.9%) +3.162
NRF2-mediated Oxidative Stress Response Cellular stress and injury 8.06E-10 53/193 (27.5%) +3.138
Mevalonate Pathway I Fatty acids and lipids biosynthesis 1.57E-06 9/13 (69.2%) +3.000
Superpathway of 
Geranylgeranyldiphosphate Biosynthesis I
Biosynthesis 3.47E-05 9/17 (52.9%) +3.000
Glutathione Redox Reactions I Biosynthesis 4.00E-03 8/24 (33.3%) +2.828
Noradrenaline and Adrenaline Degradation Hormones Degradation 1.29E-02 10/40 (25.0%) +2.530
Leucine Degradation I Amino acid degradation 1.40E-04 6/9 (66.7%) +2.449
Ethanol Degradation II Alcohols Degradation 2.13E-02 9/37 (24.3%) +2.333
Estrogen Biosynthesis Hormones Biosynthesis 2.57E-05 15/41 (36.6%) +2.324
Fatty Acid B-oxidation I Fatty acid and lipids degradation 1.25E-04 12/32 (37.5%) +2.309
Stearate Biosynthesis I Fatty acid and lipids biosynthesis 3.16E-03 12/44 (27.3%) +2.309
Ketogenesis Metabolites and Energy 3.03E-03 5/10 (50.0%) +2.236
Colanic Acid Building Blocks Biosynthesis Cell Structures Biosynthesis 1.62E-02 5/14 (35.7%) +2.236
Zymosterol Biosynthesis Fatty acids and lipids biosynthesis 2.14E-03 4/6 (66.7%) +2.000
Isoleucine Degradation I Amino Acids Degradation 4.27E-04 7/14 (50.0%) +1.890
Glutaryl-CoA Degradation Carboxylates Degradation 1.16E-03 7/16 (43.8%) +1.890
Valine Degradation I Amino Acids Degradation 2.61E-03 7/18 (38.9%) +1.890
Tryptophan Degradation X/III Amino Acids Degradation 1.93E-02 7/25 (28.0%) +1.890
Ethanol Degradation IV Alcohols Degradation 1.93E-02 7/25 (28.0%) +1.890
Androgen Signaling Nuclear receptor Signaling 3.91E-02 23/137 (16.8%) +1.667
Aldosterone Signaling in Epithelial Cells Nuclear Receptor Signaling 4.42E-02 27/168 (16.1%) +1.667
Serotonin Degradation Hormones Degradation 1.29E-02 16/77 (20.8%) +1.500
Retinoate Biosynthesis I Vitamins Biosynthesis 3.52E-02 8/34 (23.5%) +1.414
Heme Biosynthesis I Heme Biosynthesis 1.67E-03 5/9 (55.6%) +1.342
Dolichyl-diphosphooligosaccharide 
Biosynthesis
Carbohydrates Biosynthesis 5.03E-03 5/11 (45.5%) +1.342
Phenylalanine Degradation IV Amino Acids Degradation 1.62E-02 5/14 (35.7%) +1.342
y-linolenate Biosynthesis II Fatty acids and lipids biosynthesis 3.76E-02 5/17 (29.4%) +1.342
14-3-3-mediated Signaling Cell Cycle Regulation; Apoptosis 3.57E-04 29/131 (22.1%) +1.213
Putrescine Degradation III Amines and Polyamines Degradation 1.20E-02 7/23 (30.4%) +1.134
Intrinsic Prothrombin Activation Pathway Cellular Stress and Injury; cardiovascular 
signaling
6.46E-03 11/42 (26.2%) -2.333
Osteoarthritis Pathway Cellular Stress and Injury 2.73E-02 34/212 (16.0%) -2.117
Aryl Hydrocarbon Receptor Cell Cycle Regulation; Apoptosis; Xenobiotic 
Metabolism; Nuclear Receptor Signaling
2.59E-04 31/141 (22.0%) -2.111
STAT3 Pathway Cellular growth and proliferation and 
development
1.25E-03 22/97 (22.7%) -1.706
LPS-IL-1 Mediated Inhibition of RXR 
Function
Nuclear Receptor Signaling 4.57E-06 49/222 (22.1%) -1.604
Coagulation System Cellular Stress and Injury 7.38E-05 13/35 (37.1%) -1.387
Inhibition of Angiogenesis by TSP-1 Cardiovascular Signaling 3.52E-02 8/34 (23.5%) -1.342
HIPPO Signaling Organismal Growth and Development 9.08E-03 18/87 (20.7%) -1.265
Acute Phase Signaling Cytokine Signaling 1.41E-07 44/170 (25.9%) -1.219
All canonical pathways with a z-score of <−1.000 or >+1.000 are listed. Pathways with a significant z-score of ≤−2.000 or ≥+2.000 are depicted in bold. 
Genes ratio= the number and percentage of genes differentially expressed in ratio to the total number of genes involved in the pathway.
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administration after PBF led to a more homogeneous 
gene expression profile compared to AL, with a smaller 
confidence interval in healthy liver tissue. Pathway 
analysis in liver tissue based on expression differences 
between irinotecan exposed AL and PBF mice, revealed 
insights into the underlying mechanisms of the PBF-
induced protective phenotype. Firstly, response to injury 
and cytokine signaling were both reduced and NRF2-
mediated oxidative stress response was highly activated 
in the PBF mice. Since cytokines are crucial players in the 
activation and adaptation to oxidative stress, this reduction 
is evidence of increased stress resistance induced by PBF 
and may also account for the reduction in DNA damage 
in healthy tissues after chemotherapy [11]. The activation 
of NRF2 is strongly associated with the beneficial effects 
of DR [12, 13], and might precondition healthy cells to 
become protected against the damage-induced response 
of irinotecan [14–16]. Posttranscriptional validation 
is needed to further understand the exact role of these 
pathways on stress resistance and prevention of side 
effects of chemotherapy. Secondly, fatty acid metabolism 
was activated as evidenced by cholesterol, mevalonate 
and fatty acid oxidation pathways. Previous data showed 
downregulation of these pathways due to fasting alone 
[12, 17]. In our study, mice were allowed to eat ad libitum 
during ten hours after irinotecan treatment awaiting 
sacrifice to obtain tissues and blood 12 hours after 
irinotecan administration. The transition from a fasted to 
a fed state during this period may well have caused the 
upregulation of metabolism. Nevertheless, this transitional 
phase could be a contributing factor to the protective 
phenotype as fatty acid metabolism has been linked to 
resistance against the adverse effects of chemotherapy 
and resistance to SN-38 in particular via upregulation of 
transcription factor SREBF [18, 19]. Indeed, SREBF1 and 
SREBF2 were amongst the highest predicted activated 
transcription factors in our analysis. Again, further studies 
could focus on these metabolic factors and their link to 
improved chemotherapeutic resistance due to PBF.
The changes induced by PBF in healthy liver 
tissue were absent in the tumor transcriptome analysis. 
The PCA plots of the AL and PBF groups revealed a 
high heterogeneity within the tumor tissue, which is in 
contrast with the orchestrated response of the liver. The 
low number of DEPS revealed no enriched pathways due 
to PBF in tumors of irinotecan-treated mice. Therefore, 
no upstream TFs were found as well. These findings add 
to the evidence that PBF does not negatively affect the 
antitumor effect of irinotecan on tumor tissue, which is in 
line with our previous results [7, 10]. 
Previously, we have found decreased levels of 
the active metabolite of irinotecan, SN-38, in plasma as 
well as liver but not in tumor tissue of fasted mice [10]. 
Carboxylesterases (Ces) one to three are needed to convert 
irinotecan in to its active metabolite SN-38 [20]. The 
relative upregulation of the carboxylesterases in fasted 
liver tissue in this study would suggest an increased 
hydrolysis of irinotecan into SN-38 [7, 21]. However, 
Cyp3a13, which is also able to convert irinotecan into 
SN-38, was downregulated which may reduce the total 
amount of SN-38 produced. Downregulation of the ABC 
transporter ABCC2 is indicative of decreased transport 
of SN-38 out of the cell [22–24]. In addition, pathway 
analysis revealed activation of the glutathione system. 
Glutathione is associated with cellular protection, and the 
increased expression of glutathione as seen in our analysis 
Figure 3: Transcriptome analysis of tumor tissue. Unbiased principal component analyses (PCA) of tumor samples, based on 
all probe sets in the microarray. Principal component (PC) 1 is depicted on the x-axis and PC2 is depicted on the y-axis, including the 
percentage of variance explained by each PC. Each symbol represents one sample of one mouse. Samples of the same group are shown in 
the same color. Colored field represents 95% confidence intervals of the group with the circles in the same color. Abbreviations: AL, ad 
libitum; PBF, preconditioned by fasting. 
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Figure 4: (A) Heatmap and expression values of probe sets related to irinotecan metabolism in both liver and tumor. Expression levels 
are depicted as the ratio of levels of fasted divided by ad libitum fed mice. The coloring scale represents the degree of either upregulated 
(red) or downregulated (blue) expression values. (B) Overview of the pathway of irinotecan metabolism outside and inside the liver cell, 
including the transportation into the intestine. The coloring scale represents the expression values in the liver depicted as the ratio of levels 
of fasted divided by ad libitum fed mice. These levels are also depicted in figure A. Dashed arrows are suggested actions of which the exact 
mechanisms are unclear. Abbreviations: AL, ad libitum; Ces, carboxylesterase; SN-38, active metabolite of irinotecan; SN-38G, SN-38 
glucuronide form; Abcc, ATP binding cassette subfamily C; NPC/APC, carbonyloxycamptothecin; Cyp3a, cytochrome P450 3A; Ugt1a1, 
Uridine glucuronosyltransferase 1A1. 
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is in line with the decreased liver toxicity as observed in 
this study. We hypothesize that PBF alters the metabolism 
of irinotecan and protects healthy cells from its toxicity, 
while preserving its antitumor efficacy. In an earlier study, 
Huisman et al. found no significant differences in mRNA 
levels of Ces2 between AL and fasted groups in both 
liver and tumor tissue, while SN-38 levels were lowered 
in both liver and plasma [10]. However, in this study 
CES2 transcription was measured on different time points 
(i.e. one, eight and 12 hours after irinotecan injection), 
while we only have expression levels at ten hours after 
PBF which complicates a direct comparison. In contrast 
to liver tissue, changes in expression levels of enzymes 
involved in irinotecan metabolism in tumor tissue after 
PBF were far less prominent underscoring that PBF does 
not abrogate antitumor activity. 
Since pharmacokinetic studies showed that the half-
life of SN-38 is approximately 12 hours [10], we choose 
to explore the transcriptional changes at this time point, 
using one dosage of irinotecan in the therapeutic window 
in which the effects of both irinotecan and PBF would 
be maximal. Analyses of multiple time points and with 
different dosages of irinotecan would likely improve our 
understanding of the results we obtained. Finally, this 
study only partially explains how PBF changes irinotecan 
metabolism and how it protects the organism, but not the 
tumor, against irinotecan exposure. Addressing the impact 
of PBF on a posttranscriptional level will likely improve 
our understanding of the mechanisms of PBF-induced 
chemoprotection.
In conclusion, we show that three days of PBF 
results in protection against the side effects of irinotecan 
treatment and activates a protective stress response 
in healthy liver tissue. These effects were absent in 
tumor tissue, which explains why it does not abrogate 
its antitumor efficacy. These results further strengthen 
the oncologic safety of DR in cancer patients, where 
preconditioning by short-term fasting could improve both 
efficacy of treatment and quality of life in patients with 
colorectal cancer treated with irinotecan. 
MATERIALS AND METHODS
Animals
Male BALB/c mice of 6–8 weeks old, weighing 
approximately 25 grams, were obtained from Charles 
River, Maastricht, The Netherlands. Upon arrival, animals 
were housed at random in individually ventilated cages 
(n=4 animals per cage) in a licensed biomedical facility 
at Erasmus University Medical Center, Rotterdam, 
The Netherlands. Standard laboratory conditions were 
maintained, i.e. temperature ~22° C, humidity ~50%, 
and a 12 h light/12 h dark cycle. All mice had free access 
to water and food (Special Diet Services, Witham, UK) 
unless mentioned otherwise. Animals were allowed 
to acclimatize for one week before the start of the 
experiments. The experimental protocol was approved 
by the Animal Experiments Committee under the Dutch 
National Experiments on Animals Act, and complied with 
the ARRIVE and BJP guidelines [25].
C26 colon carcinoma cells
The murine colon carcinoma cell line C26, 
originally derived from the BALB/c mouse was cultured 
in Dulbecco’s Modified Eagle’s Medium (Sigma Aldrich, 
St. Louis, MO, USA), supplemented with 10% fetal 
calf serum (Lonza, Verviers, Belgium), penicillin (100 
units/ml) and streptomycin (100 units/ml) (Invitrogen, 
Auckland, New Zealand) at 37 degrees Celsius in a 5% 
carbon dioxide environment. Cells were harvested by brief 
trypsinization (0.05% trypsin in 0.02% ethylenediamine 
tetra-acetic acid (EDTA)). For subcutaneous injection, 
cells were harvested and after centrifugation, single-cell 
suspensions were prepared in phosphate buffered saline 
(PBS) to a final concentration of 2.5 × 105 cells/100 µL. 
Cell viability was determined by trypan blue staining, and 
was always ≥90%. 
Experimental setup
The exact group size for each experimental group 
(n = 6/group) was equal by design. The mice were 
randomly divided into two groups. Since food had to be 
given daily to the AL fed groups, blinding of the operators 
to the dietary intervention groups was not feasible to 
execute. Experimental setup is depicted in Supplementary 
Figure 1.
All mice (n = 12) were anaesthetized (isoflurane 
inhalation, 5% isoflurane inhalation initially and then 2% 
isoflurane with a 1:1 air: oxygen mixture for maintenance 
of anesthesia) (Supplementary Figure 1). Both flanks 
were shaved for precise injection. 2.5 × 105 C26 cells 
were injected subcutaneously on both sides in a volume 
of 100 µL, using a 21G needle. Tumors were allowed 
to grow for 12 days before start of the experiment. 
Mice were weighed and tumors were measured daily 
with digital calipers. As stated above, the mice were 
randomly divided into two groups (n = 6/group). One 
group was preconditioned by fasting (PBF) for three days 
and one group was fed AL. Subsequently, both groups 
were treated with a single weight-adjusted dose of 133 
mg/kg (±3.3 mg/kg, and ±2.7 mg/kg respectively) of 
irinotecan intraperitoneally. Two hours after injection, 
both groups received unlimited access to food for 10 
hours until the moment of sacrifice. The difference 
between starting amount and remaining amount of food 
was used to calculate food consumption per mouse 
for this 10-hour period. Subsequently, 12 hours after 
irinotecan administration, the mice were sacrificed by 
exsanguination. 
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PBF protocol
Mice in the AL fed group were allowed unrestricted 
access to food, and the amount of food consumed per cage 
was measured daily. Before the start of the PBF period, all 
mice were transferred to a clean cage and mice in the PBF 
groups were withheld food for three days starting at 4:00 
PM on a Friday until 10:00 AM on a Monday. All animals 
were given continuous access to water. 
Chemotherapy
Irinotecan, HCl-trihydrate 20 mg/mL (Hospira, 
Benelux) was used for in vivo experiments. Irinotecan 
was diluted in sodium chloride 0.9% (Braun, Melsungen, 
Germany) to a final volume of 200 µL per injection, and 
was given intraperitoneally. 
Plasma measurements of organ function
Mice were killed by exsanguination with cardiac 
puncture under anesthesia (isoflurane inhalation, 5% 
isoflurane inhalation initially and then 2% isoflurane with 
a 1:1 air: oxygen mixture for maintenance of anesthesia). 
After cardiac puncture, ± 900 µL of blood per mouse was 
transferred directly into 1 mL tubes (MiniCollect, Greiner 
Bio-one), containing EDTA. Samples were directly 
centrifuged (3,500 rpm; 10 min) after which the plasma 
was transferred to a separate tube. Plasma aspartate 
transaminase (AST), alanine transaminase (ALT), lactate 
dehydrogenase (LDH), urea, and creatinine levels were 
analyzed at the Central Clinical Chemical Laboratory 
of the Erasmus University Medical Center. Fifty µL of 
blood was used to measure the number of leukocytes with 
a Z-series Coulter Counter (Beckman Coulter, Woerden, 
The Netherlands).
Tissue sampling
Liver and tumors were collected and weighed. The 
median liver lobe was isolated for array analysis and 
directly stored in RNAlater® Solution (Life Technologies 
Europe BV, Bleijswijk, The Netherlands) and stored at 
4° C until further analysis. Viable tumor samples were 
identified at the border of the tumor tissue excluding 
necrotic parts as well as normal tissue. Only plain tumor 
tissues remained, and these samples were directly stored 
in RNAlater® until further analysis.   
RNA isolation
Plain tumor and liver samples obtained were kept 
at 4° C in RNAlater® Solution until further analyses. 
RNA isolation took place between 24 hours and 96 
hours after sample collection. Total RNA was extracted 
via the QIAzol lysis Reagent and miRNAeasy Mini 
Kits (QIAGEN, Hilden, Germany), according to Qiagen 
protocol. Concentrated buffers RPE and RWT (QIAGEN) 
for washing of membrane-bound RNA and purification 
were added mechanically by using the QIAcube 
(QIAGEN, Hilden, Germany) via the miRNeasy program. 
Subsequently, isolated RNA was stored at −80° C. RNA 
concentrations were measured using the Nanodrop 
(Thermo Fisher Scientific™, Breda, The Netherlands) and 
RNA quality was assessed using the 2100 Bio-Analyzer 
(Agilent Technologies, Amstelveen, The Netherlands), 
according to manufacturer’s instructions. The RNA 
quality was quantitatively expressed as the RNA Integrity 
Number (RIN, range 0–10). Out of the six tumor samples 
and six liver samples per group, the four samples with 
the highest RIN were used for microarray analyses. RIN-
values of the tumor samples ranged between 7.8 and 
10, the RIN-values of the liver samples ranged between 
7.6 and 8.6.
Array analysis
Microarray hybridization was done at the 
Microarray Department of the University of Amsterdam 
(The Netherlands) to Affymetrix HT MG-430 PM Array 
Plates, according to the Affymetrix protocols. For each 
group, 4 biological replicates were used. The output of the 
hybridization contained raw mean expression data put into 
CEL files. Subsequent quality control and normalization 
were done using the pipeline at the www.arrayanalysis.
org website (Maastricht University, The Netherlands) [26]. 
Normalization was performed via the Robust Multichip 
Average algorithm, and the output of the normalization 
consisted of 45141 probes [27]. Both raw and normalized 
microarray data and their MIAME compliant metadata 
were deposited at the Gene Expression Omnibus database, 
with number GSE72484 (www.ncbi.nlm.nih.gov/geo). 
Statistical analyses
For each set of parameters means and standard 
errors of the mean were computed. All standard statistical 
tests were performed using SPSS version 21 for Windows 
software (Statistical Package for Social Sciences, Chicago, 
IL, USA) and GraphPad Prism (GraphPad Software 
Inc., version 5.01). Comparison of plasma markers was 
done using the Mann-Whitney U-test for non-parametric 
data. A P-value < 0.05 was considered to be significant. 
Microarray analyses were performed using the free 
software package R (R foundation). Gene expression 
profiles were compared using the Linear Models for 
Microarray Data (limma) method with correction for 
multiple testing using the false discovery rate (FDR) 
according to Benjamini and Hochberg [28]. Fold changes 
were expressed as the geometric mean per diet group 
against the corresponding AL fed control group, and cut-
off values for a significant difference were put at FDR 
<5%. Functional annotation and analyses were performed 
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using the Ingenuity software (http://www.ingenuity.com/
products/ipa). Inhibition or activation prediction of the 
pathway analysis and upstream transcription regulators 
was predicted with Ingenuity software by calculating 
statistical z-scores based on the observed gene expression 
changes in our dataset. Via z-scores, the chance of 
significant prediction based on random data is reduced 
(http://pages.ingenuity.com/rs/ingenuity/images/0812%20
upstream_regulator_analysis_whitepaper.pdf). Cut-off 
values for a significant activation or inhibition were put at 
a z-score of ≥2 or ≤-2, respectively.
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